A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2001
10/23/2001	CA2183862C Stabilized composition for oral administration of peptides
10/23/2001	CA2106479C Stable water in oil emulsion with high silicone content
10/23/2001	CA2079342C Multi-functional pharmaceutical compounds and methods of use
10/18/2001	WO2001077687A2 Prion-binding peptidic ligands and methods of using same
10/18/2001	WO2001077360A2 Methods for ansamitocin production
10/18/2001	WO2001077145A2 Integrin binding peptide derivatives
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001076649A1 An injectable bone mineral substitute material
10/18/2001	WO2001076644A2 Lipid-based systems for targeting diagnostic agents
10/18/2001	WO2001076640A2 Chemically modified novel erythropoietin stimulating protein compositions and methods
10/18/2001	WO2001076639A2 Chemically-modified myelopoietin conjugates
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076636A2 Pharmaceutical composition of modified pna molecules
10/18/2001	WO2001076634A1 Oral delivery method and composition for solid medications or dietary supplements
10/18/2001	WO2001076633A2 Targeted transfection of cells using a biotinylated dendrimer
10/18/2001	WO2001076627A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	WO2001076619A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
10/18/2001	WO2001076608A1 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients
10/18/2001	WO2001076605A1 Minoxidil-containing preparations
10/18/2001	WO2001076601A2 Pharmaceutical compositions comprising salmeterol and ipratropium
10/18/2001	WO2001076597A2 A method of administering an antitumour compound using a polymer-camptothecin conjugate
10/18/2001	WO2001076595A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
10/18/2001	WO2001076594A1 Antimicrobial coatings
10/18/2001	WO2001076577A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	WO2001076575A2 The treatment of respiratory diseases
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076567A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	WO2001076565A1 Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
10/18/2001	WO2001076564A1 Microprojectile delivery system and particulate product
10/18/2001	WO2001076561A2 Pharmaceutical compositions
10/18/2001	WO2001076560A1 Physically stabilized dry powder formulations
10/18/2001	WO2001076559A1 Method 0f administration of paclitaxel-plasma protein formulation
10/18/2001	WO2001076558A1 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
10/18/2001	WO2001076556A2 Lipid-based drug delivery systems against parasitic infections
10/18/2001	WO2001076555A2 Lipid-based drug delivery systems for topical application
10/18/2001	WO2001076554A2 Drug delivery composition and device
10/18/2001	WO2001076553A2 Method and device for enhanced transdermal drug delivery
10/18/2001	WO2001076542A1 Hair growth stimulant compositions
10/18/2001	WO2001076531A2 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	WO2001076381A1 Protein stabilised emulsions
10/18/2001	WO2001076370A2 Anthelmintic combinations
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001035933A3 A method of microencapsulation
10/18/2001	WO2001026683A3 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses
10/18/2001	WO2001024817A3 Pharmaceutical compositions of fibrinolytic agent
10/18/2001	WO2000047130A9 Injectable collagen-based system for delivery of cells or therapeutic agents
10/18/2001	WO2000040270A3 Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28
10/18/2001	WO2000032233A3 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
10/18/2001	US20010031873 Drug delivery, antitumor agents
10/18/2001	US20010031801 Pumping active agent, polymer, and solvent, form emulsion; forming an emulsion; solvent extraction;
10/18/2001	US20010031787 Minimizing skin damage, irritation or sensitization; nontoxic; used in urogenital disorders
10/18/2001	US20010031773 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, HIV and Kaposi sarcoma, as viricides and anticarcinogenic agents
10/18/2001	US20010031769 Pharmaceutical compositions
10/18/2001	US20010031761 Compounds such as camptothecin 20-o-nonanoate; antitumor agents; low toxicity; good absorbability
10/18/2001	US20010031756 Inclusion complexes of aryl-heterocyclic salts
10/18/2001	US20010031755 Novel compositions comprising trimetrexate
10/18/2001	US20010031747 Progestin therapy for maintaining amenorrhea
10/18/2001	US20010031741 Methods for treatment of lysosomal storage diseases
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031734 Mixture with sugar and, or sugar alcohol
10/18/2001	US20010031726 Mixture of buffer, zinc, phenolic preservative and isotonic agent
10/18/2001	US20010031725 Polysaccharides
10/18/2001	US20010031498 Treating polyamine with functionalized hemiacetal in presence of titanium isopropoxide and sodium borohydride; synthetic genetic vector
10/18/2001	US20010031497 Complex of chitosan-based compound and a nucleic acid or oligonucleotide; delivers oligonucleotide into cell; non-viral gene delivery
10/18/2001	US20010031282 Dissolving solid in dimethyl ether under pressure; precipitation; separation
10/18/2001	US20010031281 Compositon to enhance permeation of topical skin agents
10/18/2001	US20010031273 Applying to skins
10/18/2001	US20010031261 Use of genetically engineered antibodies to treat multiple myeloma
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	US20010031251 Polymer
10/18/2001	US20010031039 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus
10/18/2001	US20010029959 Nicotine salts having improved taste, process for their preparation and their use
10/18/2001	DE10019171A1 Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic substances
10/18/2001	DE10016881A1 Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer Targeted transfection of cells using biotinylated dendrimer
10/18/2001	DE10016559A1 System für den Transport von Aktivstoffen in einem biologischen System System for transporting active substances in a biological system
10/18/2001	DE10015906A1 Directed gene transfer to eukaryotic cells, useful for antisense inhibition of specific genes, comprises using a complex of polyethyleneimine, nucleic acid and monoclonal antibodies
10/18/2001	DE10015463A1 High water content water-in-oil emulsion creams containing e.g. pharmaceuticals together with lecithin and short-chain di- or tri-ols are sterile filtered to give stable products with reduced secondary effects
10/18/2001	CA2409782A1 Drug delivery composition and device
10/18/2001	CA2406484A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406188A1 Methods for ansamitocin production
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405568A1 Prion-binding peptidic ligands and methods of using same
10/18/2001	CA2405554A1 Intracorporeal medicaments comprising halogenated xanthenes for high energy phototherapeutic treatment of disease
10/18/2001	CA2405360A1 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	CA2405151A1 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	CA2404645A1 Physically stabilized dry powder formulations
10/18/2001	CA2401836A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	CA2400386A1 Anthelmintic combinations
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1145722A1 Use of perfluoropolyether phosphates as preservatives of formulations for topical use
10/17/2001	EP1145719A2 Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
10/17/2001	EP1145712A1 Sustained release excipient
10/17/2001	EP1145711A1 Flash-melt oral dosage formulation
10/17/2001	EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001	EP1144623A1 Method and medicament for inhibiting the expression of a defined gene
10/17/2001	EP1144613A1 Methods for making proteins containing free cysteine residues
10/17/2001	EP1144609A2 Chimeric antisense oligonucleotides and cell transfecting formulations thereof

1 ... 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 ... 1712